



Mohamed ElSayed, PhD

EVP & Chief Technology Officer

RVAC Medicines

Dr. Mohamed ElSayed is a seasoned drug hunter with +25 years of leadership experience spanning pharmaceutical companies, biotech organizations, and academic institutions. Throughout his professional career, he led the development of transformative medicines spanning small molecules, biologics, genetic medicines, and precision therapies for multiple therapeutic indications.

Presently, as the EVP & Chief Technology Officer of a biotech firm, he is leading a global R&D organization at Waltham/MA, Shanghai/China, and Singapore focused on development of mRNA-based vaccines for the emerging markets. Before this role, Dr. ElSayed was a VP of Biotechnology at Eli Lilly where he built the Oral Biologics Platform, played a critical role in shaping Lilly's Genetic Medicines Strategy, and spearheaded multiple strategic partnerships with direct investment totaling +\$400M. Dr. ElSayed had multiple advisory and operational roles with increasing responsibilities in other biopharmaceutical companies including Abbvie, Samyang Research Corporation, and Guilford Pharmaceuticals.

Earlier in his career, Dr. ElSayed was a tenured professor at the University of Michigan where he established an internationally recognized program focused on the development of investigational therapeutics for cancer and autoimmunity. During his academic career, he received multiple honors/awards including the US National Science Foundation CAREER Award, Coulter Foundation Translational Research Partnership in Biomedical Engineering Award, and US Department of Defense Award. He co-authored +180 research articles and conference proceedings, delivered +80 invited talks, and he is an inventor of 8 patents.